Pembrolizumab additionally has been approved in the US for use in the first line setting in patients with recurrent/metastatic HNSCC, either in combination with chemotherapy or alone as monotherapy depending on tumor/tumor microenvironment PD-L1 expression (12). This evidence concerns the gene CD274 and neoplasm.